Comparison of the free and total light chain assays in serum and urine samples with immunofixation electrophoresis for detecting monoclonal proteins in patients with monoclonal gammopathy
References
- 1. Abraham R.S. et al.: Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin. Chem., 48, 655, 2002.
- 2. Bradwell A.R. et al.: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem., 47, 673, 2001.
- 3. Bradwell A.R.: Serum Free Light Chain Analysis. 6th ed. Bradwell 2010.
- 4. Bradwell A.R. et al.: Serum test for assessment of patients with Bence Jones myeloma. Lancet. 361, 489, 2003.
- 5. Brouwer J., Otting-van de Ruit M., Busking-van der Lely H.: Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin. Chim. Acta., 150, 267, 1985.
- 6. Dispenzieri A. et al.: Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 111, 785, 2008.
- 7. Dispenzieri A. et al.: Appraisal of immunoglobulin free light chain as a marker of response. Blood. 111, 4908, 2008.
- 8. Herzog W., Hoffman W.: Detection of free kappa and lambda light chains in serum and urine in patients with monoclonal gammopathy. Blood 102, 5190a, 2003.
- 9. Jaskowski T.D., Litwin C.M., Hill H.R.: Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin. Vaccine. Immunol., 13, 277, 2006.
- 10. Jenner E: Serum free light chains in clinical laboratory diagnostics. Clin. Chim. Acta 427, 15, 2014.
- 11. Katzmann J.A., Abraham R.S., Dispenzieri A.: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin. Chem., 51, 878, 2005.
- 12. Katzmann J.A., Clark R.J., Abraham R.S.: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin. Chem., 48, 1437, 2002.
- 13. Katzmann J.A., Kyle R.A., Benson J.: Screening panels for detection of monoclonal gammopathies. Clin. Chem., 55, 1517, 2009.
- 14. Kendziorek A., Bobilewicz D.M.: Badania laboratoryjne w rożnych stadiach rozwoju gammapatii monoklonalnych. In Vitro Explorer, 1, 3, 2007.
- 15. Korpysz M. et al.: Concentrations of free light chains determined by nephelometry and turbidimetry. Curr. Iss. Pharm. Med. Sci. 25, 434, 2012.
- 16. Korpysz M., Malecha-Jędraszek A., Donica H.: Blood serum free light chain concentration vs. Immunofixation results in patients with monoclonal gammopathy. Curr. Iss. Pharm. Med. Sci., 25, 430, 2012.
- 17. Lachmann H.J. et al.: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol., 122, 78, 2003.
- 18. Levinson S.S.: Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples. Clin. Chim. Acta., 412, 2206, 2011.
- 19. Levinson S.S.: Urine immunofixation electrophoresis remains important and is complementary to serum free light chain. Clin. Chem. Lab. Med., 49, 1801, 2011.
- 20. Levinson S.S., Keren D.F.: Free light chains of immunoglobulins: clinical laboratory analysis. Clin. Chem., 40, 1869, 1994.
- 21. Marien G. et al.: Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin. Chem., 48, 1600, 2002.
- 22. Nowrousian M.R. et al.: Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin. Cancer Res., 11, 8706, 2005.
- 23. Siegel D. et al.: Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies. Lab. Med., 40, 341, 2009.
- 24. Singhal S. et al.: The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood, 114, 38, 2009.
- 25. Snozek C.L. et al.: Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 22, 1933, 2008.
- 26. Snyder M.R. et al.: Quantification of urinary light chains. Clin. Chem., 54, 1744, 2008.
- 27. Solling K. et al.: Free light chains of immunoglobulins in serum from patients with leukaemias and multiple myeloma. Scand. J. Haematol., 28, 309, 1982.
- 28. Tate J.R. et al.: Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin. Chim. Acta., 376, 30, 2007.
- 29. Usnarska-Zubkiewicz L., Hołojda J., Kuliczkowski K.: Serum free light chain (sFLC) - diagnostic and prognostic value in plasma cell dyscrasias. Acta Haematol. Pol., 40, 349, 2009.
- 30. Van Hoeven K.H. et al.: Serum free light chain assays are more sensitive than urinary tests for free light chain monoclonal paraproteins. Clin. Chem., 55, C30a, 2009.
- 31. Viedma J.A., Garrigos N., Morales S.: Comparison of the sensitivity of 2 automated immunoassays with immunofixation electrophoresis for detecting urine Bence Jones proteins. Clin. Chem., 51, 1505, 2005.
Language: English
Page range: 165 - 170
Submitted on: Oct 17, 2014
Accepted on: Oct 23, 2014
Published online: Mar 3, 2015
Published in print: Sep 1, 2014
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2015 Maciej Korpysz, Marta Morawska, Agata Burska, Helena Donica, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.